Ketchem C, Lynch K
Gastroenterol Hepatol (N Y). 2025; 20(12):733-738.
PMID: 39886002
PMC: 11776008.
Andrews C, Herzlinger M, Moss S
Gastroenterol Hepatol (N Y). 2024; 20(8):469-476.
PMID: 39205950
PMC: 11348536.
Malfertheiner P, Moss S, Daniele P, Pelletier C, Jacob R, Tremblay G
Gastro Hep Adv. 2024; 1(5):824-834.
PMID: 39131848
PMC: 11307524.
DOI: 10.1016/j.gastha.2022.06.009.
Ouyang M, Zou S, Cheng Q, Shi X, Zhao Y, Sun M
Pharmaceuticals (Basel). 2024; 17(6).
PMID: 38931366
PMC: 11206580.
DOI: 10.3390/ph17060698.
Lee J, Min B, Gong E, Kim J, Na H, Ahn J
United European Gastroenterol J. 2024; 12(7):941-950.
PMID: 38887840
PMC: 11497715.
DOI: 10.1002/ueg2.12609.
Secondary Antibiotic Resistance after One or More Eradication Failure: A Genotypic Stool Analysis Study.
Losurdo G, Mezzapesa M, Ditonno I, Piazzolla M, Pricci M, Girardi B
Antibiotics (Basel). 2024; 13(4).
PMID: 38667013
PMC: 11047300.
DOI: 10.3390/antibiotics13040336.
Effectiveness of Rifabutin-Based Regimens in Treating Helicobacter pylori Infections.
Gugnani J, Abhishek F, Agarwal Y, Damera A, Kaur H, Taleb B
Cureus. 2024; 15(12):e50541.
PMID: 38222127
PMC: 10787902.
DOI: 10.7759/cureus.50541.
Efficacy and safety of high-dose ilaprazole-amoxicillin dual therapy for eradication: a prospective, single-center, randomized trial.
Cheng J, Fan C, Huang K, Zhai L, Wang H, Xie D
Front Pharmacol. 2023; 14:1272744.
PMID: 38026958
PMC: 10661892.
DOI: 10.3389/fphar.2023.1272744.
Evolving Concepts in Helicobacter pylori Management.
Moss S, Shah S, Tan M, El-Serag H
Gastroenterology. 2023; 166(2):267-283.
PMID: 37806461
PMC: 10843279.
DOI: 10.1053/j.gastro.2023.09.047.
Infections in Children.
Nguyen J, Kotilea K, Bontems P, Miendje Deyi V
Antibiotics (Basel). 2023; 12(9).
PMID: 37760736
PMC: 10525885.
DOI: 10.3390/antibiotics12091440.
A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication of : A Non-Inferiority Clinical Trial.
Li J, Lv L, Zhu Y, Zhou Z, He S
Infect Drug Resist. 2023; 16:5637-5645.
PMID: 37662977
PMC: 10473400.
DOI: 10.2147/IDR.S417711.
Helicobacter pylori infection.
Malfertheiner P, Camargo M, El-Omar E, Liou J, Peek R, Schulz C
Nat Rev Dis Primers. 2023; 9(1):19.
PMID: 37081005
PMC: 11558793.
DOI: 10.1038/s41572-023-00431-8.
Diagnosis and treatment patterns among patients with newly diagnosed Helicobacter pylori infection in the United States 2016-2019.
Shah S, Cappell K, Sedgley R, Pelletier C, Jacob R, Bonafede M
Sci Rep. 2023; 13(1):1375.
PMID: 36697470
PMC: 9876904.
DOI: 10.1038/s41598-023-28200-3.
Clinical Implication of Drug Resistance for Management.
Argueta E, Ho J, Elfanagely Y, DAgata E, Moss S
Antibiotics (Basel). 2022; 11(12).
PMID: 36551341
PMC: 9774604.
DOI: 10.3390/antibiotics11121684.
Treatment Regimens: A US Perspective.
Ho J, Argueta E, Moss S
Gastroenterol Hepatol (N Y). 2022; 18(6):313-319.
PMID: 36398140
PMC: 9666828.
Alarming antibiotics resistance of Helicobacter pylori from children in Southeast China over 6 years.
Shu X, Ye D, Hu C, Peng K, Zhao H, Li H
Sci Rep. 2022; 12(1):17754.
PMID: 36272980
PMC: 9588048.
DOI: 10.1038/s41598-022-21661-y.
Management of Infection: A Comparison between Korea and the United States.
Kim S, Hwang J
Gut Liver. 2022; 16(4):503-514.
PMID: 35843686
PMC: 9289837.
DOI: 10.5009/gnl210224.
Helicobacter pylori Infection, Its Laboratory Diagnosis, and Antimicrobial Resistance: a Perspective of Clinical Relevance.
Ansari S, Yamaoka Y
Clin Microbiol Rev. 2022; 35(3):e0025821.
PMID: 35404105
PMC: 9491184.
DOI: 10.1128/cmr.00258-21.
The Influence of Past Metronidazole Exposure on the Outcome of Eradication.
Choe Y, Kim J, Choi H, Kim D, Park J, Oh J
Front Microbiol. 2022; 13:857569.
PMID: 35401472
PMC: 8992689.
DOI: 10.3389/fmicb.2022.857569.
Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data.
Howden C, Sheldon K, Almenoff J, Chey W
Dig Dis Sci. 2021; 67(9):4382-4386.
PMID: 34862940
PMC: 9352601.
DOI: 10.1007/s10620-021-07323-5.
